Publication Name	World Journal of Gastroenterology
Manuscript ID	16871
Country	Finland

Received	2015-02-01 17:15
Peer-Review Started	2015-02-01 19:50
To Make the First Decision	2015-04-13 15:51
Return for Revision	2015-04-14 10:34
Revised	2015-05-26 00:00
Second Decision	2015-08-10 08:13
Accepted by Journal Editor-in-Chief	2015-08-10 15:02
Accepted by Executive Editor-in-Chief	2015-08-25 16:54
Articles in Press	2015-08-25 16:55
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-08-31 09:41
Publish the Manuscript Online	2015-10-14 12:06

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Editorial
Article Title	Advanced pancreatic cancer - how to choose an adequate treatment option
Manuscript Source	Invited Manuscript
All Author List	Eija A Korkeila
Funding Agency and Grant Number
Corresponding Author	Eija A Korkeila, MD, PhD, Specialist in Oncology and Radiotherapy, Department of Oncology, Turku University Hospital and University of Turku, Hämeentie 11 PB 52, 20521 Turku, Finland. eija.korkeila@tyks.fi
Key Words	Pancreatic cancer; Chemotherapy; Palliative treatment; Prognosis; Side effects
Core Tip	The prognosis of metastatic pancreatic adenocarcinoma is poor. Chemotherapy is palliative at best. Some patients benefit from treatment, while some have rapidly progressing treatment-resistant disease. There are several options for single-agent and combined treatment. Some patients may even gain benefit from treatment in second and even further lines and live substantially longer than average. Why is pancreatic cancer so resistant to treatment?
Publish Date	2015-10-14 12:06
Citation	Korkeila EA. Advanced pancreatic cancer - how to choose an adequate treatment option. World J Gastroenterol 2015; 21(38): 10709-10713
URL	http://www.wjgnet.com/1007-9327/full/v21/i38/10709.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i38.10709

Full Article (PDF)	WJG-21-10709.pdf
Full Article (Word)	WJG-21-10709.doc
Manuscript File	16871-Review.doc
Answering Reviewers	16871-Answering reviewers.pdf
Audio Core Tip	16871-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	16871-Conflict-of-interest statement.pdf
Copyright License Agreement	16871-Copyright assignment.pdf
Peer-review Report	16871-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	16871-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	16871-Scientific misconduct check.pdf
Scientific Editor Work List	16871-Scientific editor work list.pdf